Adverse events1,305

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,305

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 1: Double-blind Placebo IV	2	59	2
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV	0	62	0
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV	2	61	3
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV	1	58	1
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IV	12	341	12
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo	0	36	0
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV	1	37	1
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC	1	71	1
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC	1	71	1
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 2, Induction Period 1: Double-blind Placebo IV	19	324	21
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV	21	653	21
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo	5	174	5
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV	1	68	1
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC	2	71	2
other	ANAEMIA	Blood and lymphatic system disorders	Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC	6	71	6
other	COLITIS ULCERATIVE	Gastrointestinal disorders	Substudy 1, Induction Period 1: Double-blind Placebo IV	5	59	6
other	COLITIS ULCERATIVE	Gastrointestinal disorders	Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV	1	62	1
other	COLITIS ULCERATIVE	Gastrointestinal disorders	Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV	3	61	3
other	COLITIS ULCERATIVE	Gastrointestinal disorders	Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV	1	58	1
other	COLITIS ULCERATIVE	Gastrointestinal disorders	Substudy 1, Induction Period 1: Openlabel Risankizumab 1800mg IV	12	341	12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03398148/events

API reference For AI assistants

Adverse events1,305

Sources 3

Read this list from software.